Preclinical investigations demonstrated that inhibition of miR-92a-2-5p effectively suppressed HCC progression by targeting the PHLPP/p-AKT/β-catenin pathway [137]. The gene discussed is PHLPP1; the disease is hepatocellular carcinoma.